Imagine a world where chronic medical conditions are detected by speech acoustics early enough that a cure is a realistic prospect. A new reality where disease progression and therapeutic efficacy can be measured remotely, where voice recordings take the place of blood draws and brain scans. For Alzheimer’s Disease, and other brain diseases, speech biomarkers are the near future of improved patient outcomes. J&J and ki:elements are pioneering speech-based assessments for neurological & psychiatric diseases, modelling approved biomarkers to detect novel symptoms through natural language processing and AI. Hear how this technology is revolutionizing unmet clinical needs from a clinical trial for Alzheimer’s Disease to identifying distinctive speech changes in depressive individuals.